Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
MaaT013
Lacuna Pharma Pty Ltd
Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
1 trial -
Magnesium Pantoprazole
Takeda
GERD
1 trial -
Magnesium Pantoprazole 20 mg
Takeda
Gastric pH Control
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
3 trials -
Maralixibat
Mirum Pharmaceuticals International B.V.
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
1 trial -
Masticatory muscle training exerciser
The University of Hong Kong
Mastication
1 trial -
Matched placebo for product, Frexalimab
Sanofi-aventis Healthcare Pty Ltd
Multiple sclerosis
1 trial -
Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets
Bioprojet Pharma
Narcolepsy
1 trial -
Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral
Madrigal Pharmaceuticals EU Limited
Non-Alcoholic Steatohepatitis (NASH)
1 trial -
Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg
The George Institute
Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.
1 trial -
Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
Matching placebo tablet, JNJ-67953964
Janssen-Cilag International N.V.
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
1 trial -
Matching placebo tablet, JNJ-67953964
Janssen-Cilag International N.V.
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
1 trial -
Mavorixafor, Mavorixafor Placebo Capsules
X4 Pharmaceuticals, Inc
Neutropenias
1 trial -
Medpulser Electroporation with Bleomycin
INOVIO PHARMACEUTICALS, INC.
Head Neck Cancer
1 trial -
Medtronic Talent Stent-Graft-System
Rhythm Pharmaceuticals Netherlands B.V.
Aortic Diseases
1 trial -
Megestrol(Yining)
The First People's Hospital of Lianyungang
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Melflufen
Oncopeptides AB (publ)
Multiple Myeloma
1 trial -
Metformin plus pioglitazone
The First People's Hospital of Lianyungang
Type 2 Diabetes
1 trial -
Methoxyflurane - Penthrox
COLLEGIUM PHARMACEUTICAL, INC
ST Elevation Myocardial Infarction
1 trial -
Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules
Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
1 trial -
Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg
Hoffmann-La Roche
Progressive multiple sclerosis (PMS)
1 trial -
Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg
Hoffmann-La Roche
Multiple sclerosis (MS)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources